Next 10 |
2024-04-19 17:10:14 ET More on ContraVir Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion ends Phase ...
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX) , a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected t...
2024-04-10 12:03:39 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain Ionis Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Ionis Pharmaceuticals, Inc. (IONS) Q4 2023 Earnings Call Transc...
2024-04-09 18:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-09 10:03:48 ET More on Madrigal Pharmaceuticals Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly I...
- Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia - SHASTA-3 and SHASTA-4 Phase 3 studies to be initiated Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-...
2024-03-30 05:16:41 ET Summary Arrowhead Pharmaceuticals has faced setbacks and obstacles in securing commercial approval for its drugs, leading to a decline in its stock price. Partnerships with Janssen and Horizon Therapeutics have been terminated, and several drug candidates ha...
- Expanded Access Program initiated to make investigational plozasiran available to patients with familial chylomicronemia syndrome - New SHASTA-2 Phase 2 clinical data in patients with severe hypertriglyceridemia to be presented at ACC.24 Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR...
2024-03-20 18:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-18 17:45:43 ET More on Inventiva Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause Inventiva resumes Phase 3 study for NASH drug, stock up 6% Inventiva drops after adverse event in Phase 3 trial for NASH drug Seeking Alphaȁ...
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX) , a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected t...
2024-04-09 18:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia - SHASTA-3 and SHASTA-4 Phase 3 studies to be initiated Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-...